Following recent FDA approval of Biogen's Alzheimer antibody drug ADUHELM (TM), targeting oligomers of amyloid beta, Galimedix aims for first patients with its GAL-201 oral small molecule drug within one year.

3Brain AG has announced a new technology based on a unique combination of microchips and AI that promises to change the way drug candidates are selected at the preclinical level to enter into clinical trials - and to maximize their chances of success.

Jan-Eric Ahlfors, CEO of Fortuna Fix Inc., to present at IABS/CIRM 4th Cell Therapy Conference on June 6, 2018 in Los Angeles

Study will use innovative technology to focus on neurodegenerative diseases

A U.S. researcher says animal studies indicate fish oil contains a substance that may help people recover from strokes.